Recent Activity

Loading...

ABIO

ARCA biopharma, Inc. · NASDAQ

Performance

-1.25%

1W

+1.83%

1M

+99.4%

3M

+87.08%

6M

+95.88%

YTD

+57.82%

1Y

Profile

ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Technical Analysis of ABIO 2024-05-10

Overview:

In analyzing the technical indicators for ABIO over the last 5 days, we will delve into the trends, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key aspects, we aim to offer valuable insights and predictions for the upcoming days.

Trend Analysis:...

See more ...

Recent News & Updates